These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 28394352)

  • 1. Spatial heterogeneity in medulloblastoma.
    Morrissy AS; Cavalli FMG; Remke M; Ramaswamy V; Shih DJH; Holgado BL; Farooq H; Donovan LK; Garzia L; Agnihotri S; Kiehna EN; Mercier E; Mayoh C; Papillon-Cavanagh S; Nikbakht H; Gayden T; Torchia J; Picard D; Merino DM; Vladoiu M; Luu B; Wu X; Daniels C; Horswell S; Thompson YY; Hovestadt V; Northcott PA; Jones DTW; Peacock J; Wang X; Mack SC; Reimand J; Albrecht S; Fontebasso AM; Thiessen N; Li Y; Schein JE; Lee D; Carlsen R; Mayo M; Tse K; Tam A; Dhalla N; Ally A; Chuah E; Cheng Y; Plettner P; Li HI; Corbett RD; Wong T; Long W; Loukides J; Buczkowicz P; Hawkins CE; Tabori U; Rood BR; Myseros JS; Packer RJ; Korshunov A; Lichter P; Kool M; Pfister SM; Schüller U; Dirks P; Huang A; Bouffet E; Rutka JT; Bader GD; Swanton C; Ma Y; Moore RA; Mungall AJ; Majewski J; Jones SJM; Das S; Malkin D; Jabado N; Marra MA; Taylor MD
    Nat Genet; 2017 May; 49(5):780-788. PubMed ID: 28394352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medulloblastoma stem cells: modeling tumor heterogeneity.
    Manoranjan B; Venugopal C; McFarlane N; Doble BW; Dunn SE; Scheinemann K; Singh SK
    Cancer Lett; 2013 Sep; 338(1):23-31. PubMed ID: 22796365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
    Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
    Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis.
    Hui AB; Takano H; Lo KW; Kuo WL; Lam CN; Tong CY; Chang Q; Gray JW; Ng HK
    Clin Cancer Res; 2005 Jul; 11(13):4707-16. PubMed ID: 16000565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.
    Koch A; Hrychyk A; Hartmann W; Waha A; Mikeska T; Waha A; Schüller U; Sörensen N; Berthold F; Goodyer CG; Wiestler OD; Birchmeier W; Behrens J; Pietsch T
    Int J Cancer; 2007 Jul; 121(2):284-91. PubMed ID: 17373666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.
    Cho YJ; Tsherniak A; Tamayo P; Santagata S; Ligon A; Greulich H; Berhoukim R; Amani V; Goumnerova L; Eberhart CG; Lau CC; Olson JM; Gilbertson RJ; Gajjar A; Delattre O; Kool M; Ligon K; Meyerson M; Mesirov JP; Pomeroy SL
    J Clin Oncol; 2011 Apr; 29(11):1424-30. PubMed ID: 21098324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas.
    Schüller U; Koch A; Hartmann W; Garrè ML; Goodyer CG; Cama A; Sörensen N; Wiestler OD; Pietsch T
    Int J Cancer; 2005 Oct; 117(1):82-9. PubMed ID: 15880586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptic developmental events determine medulloblastoma radiosensitivity and cellular heterogeneity without altering transcriptomic profile.
    Malawsky DS; Weir SJ; Ocasio JK; Babcock B; Dismuke T; Cleveland AH; Donson AM; Vibhakar R; Wilhelmsen K; Gershon TR
    Commun Biol; 2021 May; 4(1):616. PubMed ID: 34021242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas.
    Waha A; Koch A; Hartmann W; Milde U; Felsberg J; Hübner A; Mikeska T; Goodyer CG; Sörensen N; Lindberg I; Wiestler OD; Pietsch T; Waha A
    Oncogene; 2007 Aug; 26(38):5662-8. PubMed ID: 17334394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
    J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Different hypermethylation status of RASSF1A in medulloblastoma and supratentorial primitive neuroectodermal tumor].
    Chang Q; Ng HK
    Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):24-8. PubMed ID: 17374234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A simplified approach using Taqman low-density array for medulloblastoma subgrouping.
    Cruzeiro GAV; Salomão KB; de Biagi CAO; Baumgartner M; Sturm D; Lira RCP; de Almeida Magalhães T; Baroni Milan M; da Silva Silveira V; Saggioro FP; de Oliveira RS; Dos Santos Klinger PH; Seidinger AL; Yunes JA; de Paula Queiroz RG; Oba-Shinjo SM; Scrideli CA; Nagahashi SMK; Tone LG; Valera ET
    Acta Neuropathol Commun; 2019 Mar; 7(1):33. PubMed ID: 30832734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of hTERT and Histone 3 Mutations in Medulloblastoma.
    Viana-Pereira M; Almeida GC; Stavale JN; Malheiro S; Clara C; Lobo P; Pimentel J; Reis RM
    Pathobiology; 2017; 84(2):108-113. PubMed ID: 27694758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Max-binding protein MNT in human medulloblastomas.
    Sommer A; Waha A; Tonn J; Sörensen N; Hurlin PJ; Eisenman RN; Lüscher B; Pietsch T
    Int J Cancer; 1999 Sep; 82(6):810-6. PubMed ID: 10446446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of lower levels of SNAP25 using multiple microarray systems and its functional significance in medulloblastoma.
    Huang CJ; Lee CL; Liu CY; Huang SH; Hou JW; Chen YH; Chien CC; Ho CM; Lo WC; Hung KL
    Int J Mol Med; 2017 May; 39(5):1195-1205. PubMed ID: 28339008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene.
    Kraus JA; Oster C; Sörensen N; Berthold F; Schlegel U; Tonn JC; Wiestler OD; Pietsch T
    Neuropathol Appl Neurobiol; 2002 Apr; 28(2):136-41. PubMed ID: 11972800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpressed TP73 induces apoptosis in medulloblastoma.
    Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
    BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
    Grotzer MA; Hogarty MD; Janss AJ; Liu X; Zhao H; Eggert A; Sutton LN; Rorke LB; Brodeur GM; Phillips PC
    Clin Cancer Res; 2001 Aug; 7(8):2425-33. PubMed ID: 11489822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.